Other substances

Crizotinib

A selective receptor proteine-tyrosine kinase inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Crizotinib on DrugBank
Crizotinib on PubChem

Marketed as

XALKORI

 

Structure image - Crizotinib

C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

Supporting references

Link Tested on Impact factor Notes Publication date
Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis
Small molecule In silico Screening 		in silico (protein-protein interaction network analysis) 2.31

Computationally predicted to be efficacious in COVID-19 treatment based on protein-protein interaction network analysis.

 Mar/12/2021

AI-suggested references

Link Publication date
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient.
Sep/13/2021
Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses
Jul/08/2020
Export (.csv)